Zydus Healthcare

Impact in US among the worst in the past 10 years

Zydus Lifesciences Ltd on Friday said it has launched the generic version of sitagliptin in India under the brand names Sitaglyn and Siglyn to address type 2 diabetes.

Zydus Lifesciences on Tuesday said its chairman Pankaj R Patel has been appointed as a part time non-official director in the central board of the Reserve Bank of India (RBl). The Appointments Committee of the Cabinet (ACC) has approved the proposal of appointment of Patel for a period of four years from the date of notification of his appointment, or until further orders, whichever is earlier, the drug maker said in a statement. Patel is already on the board of various institutions, including Invest India, Member of the Mission Steering Group (MSG) -- the highest policy making and steering body constituted under National Health Mission (NHM), and of the Drug Technical Advisory Board by the ministry of health & family welfare, it added. He is also the chairman of the Board of Governors and Society, IIM, Udaipur and a member of the Board of Governors of the Indian Institute of Management (IIM), Ahmedabad. Patel was also the president of the Federation of Indian Chamber of Commerce

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market Nitroglycerin Sublingual tablets, used to treat chest pain, in the American market.

Both drugs, Mifegest Cytolog are used for medical termination of pregnancy

Multiples' deal ticket size in the first fund was only $30 million and in the second around $50 million

Drug firm Zydus Cadila on Thursday said it has received final approval from the US health regulator to market Ibrutinib Capsules, used to treat certain cancers

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

The company has launched its Dapagliflozin tablets in the strengths of 10 mg and 5 mg priced at ₹17 and ₹14

With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.

Zydus Healthcare is a wholly owned subsidiary of Cadila Healthcare

It bought Walia Business Park building on Western Express Highway in Goregaon East

Estimated market size of the two ANDAs put together is nearly $200 million, the company said